PTPN2 and cancer: Among them, compound Tegeprotafib and Osunprotafib are the only two PTP1B inhibitors which are in clinical phase I for cancer treatment, both of them are also potent T-cell protein tyrosine phosphatase (TCPTP) inhibitors29, and compound Ertiprotafib and Trodusquemine are failed in clinical trials for diabetic treatment because of insufficient therapeutic effect or occurrence of side effects (Table 1) .30